{"id":4108,"date":"2025-10-01T16:11:15","date_gmt":"2025-10-01T16:11:15","guid":{"rendered":"https:\/\/vantagebiotrials.com\/?p=4108"},"modified":"2025-10-02T13:45:45","modified_gmt":"2025-10-02T13:45:45","slug":"vantage-biotrials-awarded-phase-3-clinical-trial-in-substance-use-disorder","status":"publish","type":"post","link":"https:\/\/vantagebiotrials.com\/fr\/vantage-biotrials-awarded-phase-3-clinical-trial-in-substance-use-disorder\/","title":{"rendered":"Vantage BioTrials Awarded Phase 3 Clinical Trial in Substance Use Disorder"},"content":{"rendered":"

\"\"<\/strong><\/p>\n

October 1, 2025, Montr\u00e9al, Canada<\/strong> \u2013 Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to announce its award and upcoming role in managing a pivotal Phase III randomized, double-blind, placebo-controlled clinical trial in the field of Substance Use Disorder.<\/p>\n

The study, sponsored by a biopharmaceutical company, aims to evaluate the safety and efficacy of an investigational approach for improving clinical reliability in treatment and monitoring settings. Due to reasons of confidentiality, specific trial details and investigational methods are not being disclosed at this time.<\/p>\n

\u201cWe are honored to be chosen as the CRO partner for this important late-phase study,\u201d said Vatche Bartekian, President of Vantage BioTrials. \u201cSubstance Use Disorder continues to pose a significant global health challenge. This trial aligns with our mission to support sponsors in conducting high-quality, risk-based, and patient-centric clinical research.\u201d<\/p>\n

Vantage BioTrials will provide full-service clinical trial management including project oversight, site management, monitoring, data review, and quality assurance\u2014leveraging its deep expertise in regulatory compliance and operational excellence.<\/p>\n

The trial has officially commenced, with patient enrollment scheduled to begin in November 2025.<\/p>\n

This award marks another important milestone in Vantage BioTrials’ growing portfolio of late-phase studies in CNS, addiction medicine, and behavioral health\u2014demonstrating the company’s capability to manage complex, high-impact trials from start to finish.<\/p>\n

 <\/p>\n

About Vantage BioTrials Inc.<\/strong><\/p>\n

Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology, and medical device industries. Known for its personalized service model, strategic value, and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector.<\/p>\n

For more information about this Press Release or Vantage BioTrials\u2019 services and capabilities, please visit www.vantagebiotrials.com<\/a> or email us at info@vantagebiotrials.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

October 1, 2025, Montr\u00e9al, Canada \u2013 Vantage BioTrials, a leading Canadian Contract Research Organization (CRO) specializing in clinical trial management services, is proud to announce its award and upcoming role in managing a pivotal Phase III randomized, double-blind, placebo-controlled clinical trial in the field of Substance Use Disorder. The study, sponsored by a biopharmaceutical company, aims to evaluate the safety and efficacy of an investigational approach for improving clinical reliability in treatment and monitoring settings. Due to reasons of confidentiality, specific trial details and investigational methods are not being disclosed at this time. \u201cWe are honored to be chosen as the CRO partner for this important late-phase study,\u201d said Vatche Bartekian, President of Vantage BioTrials. \u201cSubstance Use Disorder continues to pose a significant global health challenge. This trial aligns with our mission to support sponsors in conducting high-quality, risk-based, and patient-centric clinical research.\u201d Vantage BioTrials will provide full-service clinical trial management including project oversight, site management, monitoring, data review, and quality assurance\u2014leveraging its deep expertise in regulatory compliance and operational excellence. The trial has officially commenced, with patient enrollment scheduled to begin in November 2025. This award marks another important milestone in Vantage BioTrials’ growing portfolio of late-phase studies in CNS, addiction medicine, and behavioral health\u2014demonstrating the company’s capability to manage complex, high-impact trials from start to finish.   About Vantage BioTrials Inc. Vantage BioTrials is a Canadian-owned Contract Research Organization (CRO) that provides Phase I-IV clinical trial management services to the pharmaceutical, biotechnology, and medical device industries. Known for its personalized service model, strategic value, and commitment to quality, Vantage BioTrials uses innovative clinical trial management strategies focused on patient safety and the acceleration of new therapies to market. We offer a complete and integrated suite of full-service solutions designed to deliver operational efficiency at a competitive value across the life sciences sector. For more information about this Press Release or Vantage BioTrials\u2019 services and capabilities, please visit www.vantagebiotrials.com or email us at info@vantagebiotrials.com.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[18,20],"tags":[],"class_list":["post-4108","post","type-post","status-publish","format-standard","hentry","category-news-homepage","category-news-pressroom","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=4108"}],"version-history":[{"count":1,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4108\/revisions"}],"predecessor-version":[{"id":4913,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/4108\/revisions\/4913"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=4108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=4108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=4108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}